Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA
Marketing
Novartis earns FDA ire for ‘misleading’ Fabhalta ad imagery
The FDA is not feeling the love in a commercial for Novartis’ paroxysmal nocturnal hemoglobinuria treatment Fabhalta.
Andrea Park
Sep 30, 2025 11:12am
Eli Lilly's oral SERD Inluriyo crosses FDA finish line
Sep 25, 2025 3:35pm
FDA takes close look at mifepristone REMS program
Sep 25, 2025 11:00am
Moderna says updated mNEXSPIKE induces strong immune response
Sep 23, 2025 10:15am
Issues at Novo site delay Scholar Rock's bid for SMA approval
Sep 23, 2025 9:19am
FDA urges doctors to minimize Tylenol use during pregnancy
Sep 23, 2025 8:55am
